Natural history, treatment, and long-term follow up of patients with multiple endocrine neoplasia type 2B: an international, multicentre, retrospective study.
Adolescent
Adrenal Gland Neoplasms
/ mortality
Adult
Carcinoma, Neuroendocrine
/ mortality
Child
Child, Preschool
Female
Follow-Up Studies
Humans
Infant
International Agencies
Male
Middle Aged
Multiple Endocrine Neoplasia Type 2b
/ mortality
Pheochromocytoma
/ mortality
Prognosis
Retrospective Studies
Survival Rate
Thyroid Neoplasms
/ mortality
Thyroidectomy
/ mortality
Young Adult
Journal
The lancet. Diabetes & endocrinology
ISSN: 2213-8595
Titre abrégé: Lancet Diabetes Endocrinol
Pays: England
ID NLM: 101618821
Informations de publication
Date de publication:
03 2019
03 2019
Historique:
received:
19
10
2018
revised:
16
11
2018
accepted:
16
11
2018
pubmed:
21
1
2019
medline:
22
5
2020
entrez:
21
1
2019
Statut:
ppublish
Résumé
Multiple endocrine neoplasia type 2B is a rare syndrome caused mainly by Met918Thr germline RET mutation, and characterised by medullary thyroid carcinoma, phaeochromocytoma, and extra-endocrine features. Data are scarce on the natural history of multiple endocrine neoplasia type 2B. We aimed to advance understanding of the phenotype and natural history of multiple endocrine neoplasia type 2B, to increase awareness and improve detection. This study was a retrospective, multicentre, international study in patients carrying the Met918Thr RET variant with no age restrictions. The study was done with registry data from 48 centres globally. Data from patients followed-up from 1970 to 2016 were retrieved from May 1, 2016, to May 31, 2018. Our primary objectives were to determine overall survival, and medullary thyroid carcinoma-specific survival based on whether the patient had undergone early thyroidectomy before the age of 1 year. We also assessed remission of medullary thyroid carcinoma, incidence and treatment of phaeochromocytoma, and the penetrance of extra-endocrine features. 345 patients were included, of whom 338 (98%) had a thyroidectomy. 71 patients (21%) of the total cohort died at a median age of 25 years (range <1-59). Thyroidectomy was done before the age of 1 year in 20 patients, which led to long-term remission (ie, undetectable calcitonin level) in 15 (83%) of 18 individuals (2 patients died of causes unrelated to medullary thyroid carcinoma). Medullary thyroid carcinoma-specific survival curves did not show any significant difference between patients who had thyroidectomy before or after 1 year (comparison of survival curves by log-rank test: p=0·2; hazard ratio 0·35; 95% CI 0.07-1.74). However, there was a significant difference in remission status between patients who underwent thyroidectomy before and after the age of 1 year (p<0·0001). There was a significant difference in remission status between patients who underwent thyroidectomy before and after the age of 1 year (p<0·0001). In the other 318 patients who underwent thyroidectomy after 1 year of age, biochemical and structural remission was obtained in 47 (15%) of 318 individuals. Bilateral phaeochromocytoma was diagnosed in 156 (50%) of 313 patients by 28 years of age. Adrenal-sparing surgery was done in 31 patients: three (10%) of 31 patients had long-term recurrence, while normal adrenal function was obtained in 16 (62%) patients. All patients with available data (n=287) had at least one extra-endocrine feature, including 106 (56%) of 190 patients showing marfanoid body habitus, mucosal neuromas, and gastrointestinal signs. Thyroidectomy done at no later than 1 year of age is associated with a high probability of cure. The reality is that the majority of children with the syndrome will be diagnosed after this recommended age. Adrenal-sparing surgery is feasible in multiple endocrine neoplasia type 2B and affords a good chance for normal adrenal function. To improve the prognosis of such patients, it is imperative that every health-care provider be aware of the extra-endocrine signs and the natural history of this rare syndrome. The implications of this research include increasing awareness of the extra-endocrine symptoms and also recommendations for thyroidectomy before the age of 1 year. None.
Sections du résumé
BACKGROUND
Multiple endocrine neoplasia type 2B is a rare syndrome caused mainly by Met918Thr germline RET mutation, and characterised by medullary thyroid carcinoma, phaeochromocytoma, and extra-endocrine features. Data are scarce on the natural history of multiple endocrine neoplasia type 2B. We aimed to advance understanding of the phenotype and natural history of multiple endocrine neoplasia type 2B, to increase awareness and improve detection.
METHODS
This study was a retrospective, multicentre, international study in patients carrying the Met918Thr RET variant with no age restrictions. The study was done with registry data from 48 centres globally. Data from patients followed-up from 1970 to 2016 were retrieved from May 1, 2016, to May 31, 2018. Our primary objectives were to determine overall survival, and medullary thyroid carcinoma-specific survival based on whether the patient had undergone early thyroidectomy before the age of 1 year. We also assessed remission of medullary thyroid carcinoma, incidence and treatment of phaeochromocytoma, and the penetrance of extra-endocrine features.
FINDINGS
345 patients were included, of whom 338 (98%) had a thyroidectomy. 71 patients (21%) of the total cohort died at a median age of 25 years (range <1-59). Thyroidectomy was done before the age of 1 year in 20 patients, which led to long-term remission (ie, undetectable calcitonin level) in 15 (83%) of 18 individuals (2 patients died of causes unrelated to medullary thyroid carcinoma). Medullary thyroid carcinoma-specific survival curves did not show any significant difference between patients who had thyroidectomy before or after 1 year (comparison of survival curves by log-rank test: p=0·2; hazard ratio 0·35; 95% CI 0.07-1.74). However, there was a significant difference in remission status between patients who underwent thyroidectomy before and after the age of 1 year (p<0·0001). There was a significant difference in remission status between patients who underwent thyroidectomy before and after the age of 1 year (p<0·0001). In the other 318 patients who underwent thyroidectomy after 1 year of age, biochemical and structural remission was obtained in 47 (15%) of 318 individuals. Bilateral phaeochromocytoma was diagnosed in 156 (50%) of 313 patients by 28 years of age. Adrenal-sparing surgery was done in 31 patients: three (10%) of 31 patients had long-term recurrence, while normal adrenal function was obtained in 16 (62%) patients. All patients with available data (n=287) had at least one extra-endocrine feature, including 106 (56%) of 190 patients showing marfanoid body habitus, mucosal neuromas, and gastrointestinal signs.
INTERPRETATION
Thyroidectomy done at no later than 1 year of age is associated with a high probability of cure. The reality is that the majority of children with the syndrome will be diagnosed after this recommended age. Adrenal-sparing surgery is feasible in multiple endocrine neoplasia type 2B and affords a good chance for normal adrenal function. To improve the prognosis of such patients, it is imperative that every health-care provider be aware of the extra-endocrine signs and the natural history of this rare syndrome. The implications of this research include increasing awareness of the extra-endocrine symptoms and also recommendations for thyroidectomy before the age of 1 year.
FUNDING
None.
Identifiants
pubmed: 30660595
pii: S2213-8587(18)30336-X
doi: 10.1016/S2213-8587(18)30336-X
pmc: PMC8132299
mid: NIHMS1696171
pii:
doi:
Types de publication
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
213-220Subventions
Organisme : Intramural NIH HHS
ID : ZIE BC011516
Pays : United States
Commentaires et corrections
Type : CommentIn
Type : ErratumIn
Informations de copyright
Copyright © 2019 Elsevier Ltd. All rights reserved.
Références
Cancer. 2002 Jan 1;94(1):44-50
pubmed: 11815959
J Clin Endocrinol Metab. 2018 Jan 1;103(1):235-243
pubmed: 29077903
Endocr Relat Cancer. 2018 Feb;25(2):T29-T39
pubmed: 28698189
Surgery. 1994 Dec;116(6):1017-23
pubmed: 7985081
J Clin Endocrinol Metab. 2013 Nov;98(11):E1813-9
pubmed: 24030942
J Clin Endocrinol Metab. 2017 Jun 1;102(6):2069-2074
pubmed: 28323957
JAMA. 1996 Nov 20;276(19):1575-9
pubmed: 8918855
Ann Surg. 2014 Apr;259(4):800-6
pubmed: 23979292
Proc Natl Acad Sci U S A. 1994 Feb 15;91(4):1579-83
pubmed: 7906417
Eur J Endocrinol. 2013 Apr 15;168(5):683-7
pubmed: 23416954
Lancet Oncol. 2014 May;15(6):648-55
pubmed: 24745698
Hum Mol Genet. 1994 Feb;3(2):237-41
pubmed: 7911697
Surgery. 2008 Dec;144(6):1044-50; discussion 1050-3
pubmed: 19041016
Endocr Relat Cancer. 2017 Jul;24(7):L39-L42
pubmed: 28438782
Nat Rev Endocrinol. 2011 Aug 23;7(10):596-607
pubmed: 21862994
J Clin Endocrinol Metab. 2019 Jan 1;104(1):7-12
pubmed: 30113649
Thyroid. 2015 Jun;25(6):567-610
pubmed: 25810047
Surgery. 1995 Dec;118(6):936-42
pubmed: 7491537
Ann Surg Oncol. 2008 Jan;15(1):293-301
pubmed: 17963006